Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Here’s a look at the Benzinga Stock Whisper Index for the week of Sept. 6:
Oracle Corporation ORCL: The technology giant is seeing strong interest from Benzinga readers ahead of Monday’s first-quarter financial results.
The company is expected to report earnings per share of $1.33, up from $1.19 in last year’s first quarter, according to data from Benzinga Pro. The company has beaten earnings per share estimates from analysts in seven straight quarters and eight of the past 10 quarters overall.
Analysts estimate the company will report first-quarter revenue of $13.24 billion, up from $12.94 billion in last year’s first quarter. The company has missed revenue estimates from analysts in four straight quarters and six of the past 10 quarters overall.
Oracle highlighted AI demand in the fourth quarter with more than 30 AI sales contracts valued at over $12.5 billion signed, including a large contract with OpenAI. Oracle also announced a partnership with Google Cloud at the time.
Oracle shares are up 2.3% over the last five days, as seen on the Benzinga Pro chart below. Oracle stock is up 38% year-to-date in 2024.
Novavax Inc NVAX: Shares of the vaccine company were up over 4% in the past five days with news that the FDA granted Emergency Use Authorization of the company’s updated COVID-19 vaccine. The updated vaccine is included in the recommendations from the U.S. Centers for Disease Control and Prevention (CDC).
The vaccine is the only protein-based option available in the U.S. for people aged 12 and older for the prevention of COVID-19. The company could also be drawing interest from investors ahead of two company presentations next week. Novavax will present at H.C. Wainwright and Baird investor conferences on Monday, Sept. 9 and Tuesday, Sept. 10, respectively.
Wheeler Real Estate Investment Trust WHLR: Shares of the real estate investment trust surged over 500% on the week after the company announced a circuit court affirmed the dismissal of a class action lawsuit involving holders of Cedar Realty preferred stock. Wheeler acquired Cedar in August 2022 and the lawsuit alleged a breach of contract related to Cedar’s former board of directors.
“With this matter behind us, both companies remain well-positioned to execute on their strategic plans,” Cedar and Wheeler CEO Andrew Franklin said.
The company owns 77 grocery-anchored shopping centers in the Northeast, Mid-Atlantic and Southeast covering 14 states. With the lawsuit behind the company, investors could see a positive long-term outlook.
Equinix Inc EQIX: The data center company saw strong interest from investors on the week with shares up minimally. The company announced it issued $750 million in green bonds across two completed offerings. The green bonds are being used to help with sustainability initiatives for the company.
“Green bonds serve as a valuable means to secure funding and support significant initiatives that enhance the sustainability of our operations,” Equinix SVP Corporate Finance and Sustainability Katrina Rymill said. “Over the last five years, our green bonds have funded 172 green building projects across 105 sites, 33 energy efficient projects and two Power Purchase Agreement projects.”
The new green bonds could help the company continue to invest in new efforts to help support the company’s 86 consecutive quarters of top-line revenue growth, which the company said is the longest streak of any S&P 500 company.
Tenon Medical Inc TNON: Investor interest in the medical device company grew during the week thanks to two items. The company announced a 1:8 reverse stock split on Sept. 4 that took effect on Sept. 6. Reverse stock splits often draw attention from retail investors as they reduce the float and shares outstanding of a company.
Tenon also announced a peer-reviewed publication of its Catamaran SI Joint Fusion System. The peer review showed evidence of fusion at the 12-month mark post-procedure, the company said.
Stay tuned for next week’s report, and follow Benzinga Pro for all the latest headlines and top market-moving stories here.
Read the latest Stock Whisper Index reports here:
Read Next:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AdvisorShares Announces Reverse Split of ETF
BETHESDA, Md., Aug. 30, 2024 /PRNewswire/ — AdvisorShares, a leading sponsor of actively managed exchange-traded funds (ETFs), has announced a reverse split of the issued and outstanding shares of the AdvisorShares Psychedelics ETF. The split will not change the total value of a shareholder’s investment.
Effective before market open on September 10, 2024, the Fund will affect a reverse split of its issued and outstanding shares as follows:
|
Fund Name |
Reverse Split Ratio |
Approximate decrease in total |
|
AdvisorShares Psychedelics ETF |
1 for 10 |
90 % |
Please note the CUSIP changes, effective September 10, 2024:
|
Fund Name |
Ticker |
Current CUSIP |
New CUSIP |
|
AdvisorShares Psychedelics ETF |
PSIL |
00768Y362 |
00768Y297 |
As a result of this reverse split, every ten shares of the Fund will be exchanged for one share as indicated above. Accordingly, the total number of the issued and outstanding shares for the Fund will decrease by the approximate percentage indicated above. In addition, the per share net asset value (NAV) and next day’s opening market price will be approximately ten times higher for the Fund. Shares of the Fund will begin trading on the NYSE Arca on a split-adjusted basis on September 10, 2024.
A shareholder’s investment value will not be affected by the reverse split. The table below illustrates the effect of a hypothetical one-for-ten reverse split anticipated for the Fund, as applicable and described above:
1-for-10 Reverse Split
|
Period |
# of Shares Owned |
Hypothetical NAV |
Total Market Value |
|
Pre-Split |
100 |
$10 |
$1,000 |
|
Post-Split |
10 |
$100 |
$1,000 |
The Trust’s transfer agent will notify the Depository Trust Company (DTC) of the reverse split and instruct DTC to adjust each shareholder’s investment(s) accordingly. DTC is the registered owner of the Fund’s shares and maintains a record of the Fund’s record owners.
Redemption of Fractional Shares and Tax Consequences for the Reverse Split
As a result of the reverse split, a shareholder of the Fund’s shares potentially could hold a fractional share. However, fractional shares cannot trade on the NYSE Arca. Thus, the Fund will redeem for cash a shareholder’s fractional shares at the Fund’s split-adjusted NAV as of the Effective Date. A shareholder could recognize a gain or loss in connection with the redemption of the shareholder’s fractional shares.
“Odd Lot” Unit
As a result of the reverse split, the Fund may have outstanding one aggregation of less than 5,000 shares to make a creation unit, or an “odd lot unit.” Thus, the Fund will provide one authorized participant with a one-time opportunity to redeem the odd lot unit after the split-adjusted NAV is struck on September 10. 2024.
About AdvisorShares
AdvisorShares is a leading provider of actively managed ETFs. For financial professionals and investors requesting more information, call 1-877-843-3831 or visit www.advisorshares.com. Follow @AdvisorShares on X(Twitter) and LinkedIn for more insights.
Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the Fund, please call 1-877-843-3831 or visit our website at www.advisorshares.com. Read the prospectus or summary prospectus carefully before investing.
Foreside Fund Services, LLC, distributor.
There is no guarantee that the Fund will achieve its investment objective. An investment in the Fund is subject to risk, including the possible loss of principal amount invested.
Psychedelic drugs, also known as hallucinogens, are a group of substances, including psilocybin, that are used to change and enhance sensory perceptions, thought processes, and energy levels. Psychedelic medicines, therapeutics, and healthcare treatments may be used in the treatment of illnesses such as depression, addiction, anxiety and post-traumatic stress disorder. Psychedelic medicine companies include life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry including producers or distributors of psychedelic medicines, biotechnology companies engaged in research and development of psychedelic medicines, and companies that are part of the supply chain for psychedelics.
Psychedelics Companies Risk. Psychedelics companies are subject to various laws and regulations that may differ at the state/local and federal level. These laws and regulations may significantly affect a psychedelics company’s ability to secure financing, impact the market for psychedelics and business sales and services, and set limitations on psychedelics use, production, transportation, and storage. There can be no guarantees that such approvals or administrative actions will happen or be favorable for psychedelics companies, and such actions may be subject to lengthy delays, and may require length and expensive clinical trials. Additionally, therapies containing controlled substances may generate public controversy. Political and social pressures and adverse publicity could lead to delays in approval of, and increased expenses for, companies and any future therapeutic candidates they may develop. All of these factors and others may prevent psychedelics companies from becoming profitable, which may materially affect the value of certain Fund investments. In addition, psychedelics are subject to the risks associated with the biotechnology and pharmaceutical industries.
In Canada, certain psychedelic drugs, including psilocybin, are classified as Schedule III drugs under the Controlled Drugs and Substances Act (“CDSA”) and, as such, medical and recreational use is illegal under Canadian federal laws. In the United States, certain psychedelic drugs, including psilocybin, are classified as Schedule I drugs under the Controlled Substances Act (“CSA”) and the Controlled Substances Import and Export Act (the “CSIEA”) and, as such, medical and recreational use is illegal under the U.S. federal laws. There is no guarantee that psychedelic drugs or psychedelic-inspired drugs will ever be approved as medicines in either jurisdiction.
In the United States, scheduling determinations by the Drug Enforcement Agency (“DEA”) are dependent on Food and Drug Administration (“FDA”) approval of a substance or a specific formulation of a substance. Unless and until psilocybin, psilocin, or other psychedelics-based products receive FDA approval, such products may be prohibited from sale, which could limit the growth opportunities for certain portfolio companies of the Fund. Even if approved by the FDA, the manufacture, importation, exportation, domestic distribution, storage, sale, and legitimate use of such products will continue to be subject to a significant degree of regulation by the DEA.
Security prices of small cap companies may be more volatile than those of larger companies and therefore the Fund’s share price may be more volatile than those of funds that invest a larger percentage of their assets in securities issued by larger-cap companies. These risks are even greater for micro-cap companies.
View original content to download multimedia:https://www.prnewswire.com/news-releases/advisorshares-announces-reverse-split-of-etf-302235282.html
SOURCE AdvisorShares
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Why Sonoma Pharmaceuticals (SNOA) Stock Is Moving
Sonoma Pharmaceuticals Inc SNOA shares are trading lower by 11.9% to $0.19 Wednesday morning after the company announced a 1-for-20 reverse stock split.
The stock will trade on a split-adjusted basis starting August 30, 2024. This move aims to meet Nasdaq’s $1.00 minimum bid price requirement. As a result, every 20 shares of Sonoma’s common stock will be consolidated into one share, reducing the total outstanding shares from 20 million to 1 million.
No fractional shares will be issued; instead, shareholders will receive cash for any fractions. The authorized shares will also increase from 24 million to 50 million.
Should I Sell My SNOA Stock?
Whether to sell or hold a stock largely depends on an investor’s strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Sonoma Pharmaceuticals have lost 75.9% year to date. This compares to the average annual return of -66.61%, meaning the stock has underperformed its historical averages. Investors can compare a stock’s movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
SNOA has a 52-week high of $1.02 and a 52-week low of $0.12.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
IMPERIAL EQUITIES INC. GRANTS STOCK OPTIONS
EDMONTON, AB, Aug. 27, 2024 /CNW/ – Imperial Equities Inc. IEI, through its Board of Directors today announced that effective August 26th, 2024, it has approved a grant of stock options to a Director and Officer of Imperial Equities Inc.
The Director can purchase an aggregate of 200,000 common shares at an exercise price of $4.00 per common share pursuant to its stock option plan. The stock options expire five years from the date of grant, and vest immediately.
About Imperial Equities Inc:
Based in Edmonton, Alberta, Imperial Equities Inc. is a publicly traded company anchored by industrial, agricultural, and commercial real estate properties in its targeted markets throughout Western Canada.
Additional information is available at: www.imperialequities.com. Imperial’s common shares are listed on the TSX Venture Exchange under symbol IEI.
Neither TSX Venture nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
SOURCE Imperial Equities Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2024/27/c3553.html
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
SenesTech Announces Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on July 25, 2024
PHOENIX, July 23, 2024 /PRNewswire/ — SenesTech, Inc. SNES “, SenesTech”, or the “, Company”, ))) (www.senestech.com) the leader in fertility control to manage animal pest populations, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:01 p.m, Eastern Time, on July 24, 2024. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “SNES” and will begin trading on a split-adjusted basis when the market opens on July 25, 2024.
At the annual meeting of stockholders held on July 11, 2024, the Company’s stockholders granted the Company’s Board of Directors the discretion to effect a reverse stock split of the Company’s common stock through an amendment to its Amended and Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-20, with such ratio to be determined by the Company’s Board of Directors.
At the effective time of the reverse stock split, every 10 shares of the Company’s issued common stock will be converted automatically into one issued share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-10 reverse stock split. It is not necessary for stockholders holding shares of the Company’s common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the reverse stock split will either be (i) rounded up to the nearest whole share of common stock, if such shares of common stock are held directly; or (ii) rounded down to the nearest whole share of common stock, if such shares are subject to an award granted under the Company’s 2018 Equity Incentive Plan, in order to comply with the requirements of Sections 409A and 424 of the Internal Revenue Code of 1986. The reverse stock split will reduce the number of issued shares of the Company’s common stock from 5,144,632 shares to approximately 514,464 shares. Proportional adjustments will be made to the number of shares of the Company’s common stock issuable upon exercise or conversion of SenesTech’s equity awards and warrants, as well as the applicable exercise price. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record may direct questions to the Company’s transfer agent, Transfer Online, Inc., at (503) 227-2950.
About SenesTech
We are committed to improving the health of the world by humanely managing animal pest populations through fertility control. We are experts in fertility control to manage animal pest populations. We invented ContraPest®, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve™, an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. We strive for clean cities, efficient businesses, and happy households – with a product designed to be humane, effective and sustainable.
For more information visit https://senestech.com/.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, the expected timing of the reverse stock split and number of shares outstanding after the reverse stock split. Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as “believe,” “may,” “future,” “plan,” “will,” “should,” “expect,” “anticipate,” “eventually,” “project,” “estimate,” “continuing,” “intend” and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; our ability to regain and maintain compliance with Nasdaq’s continued listing requirements; and regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACT:
Investors: Robert Blum, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com
Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143
View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-announces-reverse-stock-split-302204232.html
SOURCE SenesTech, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Why Evoke Pharma (EVOK) Stock Is Volatile
Evoke Pharma Inc EVOK shares ended Tuesday down 16.40% to 42 cents after the company announced a 1-for-12 reverse stock split of its common stock, set to take effect at 12:01 a.m. ET on August 1, 2024. After-hours trading has it up 12.44% at 47 cents.
The reverse stock split means that every 12 shares of the company’s existing common stock will be consolidated into one share. The stock will trade on a split-adjusted basis on NASDAQ under the same symbol, EVOK, starting Aug. 1.
This reverse split, approved by shareholders at the 2024 annual meeting, will not change the par value or the authorized number of shares. Fractional shares will not be issued; instead, shareholders will receive a cash payment for any fractional shares.
Should I Buy, Hold or Sell My EVOK Stock?
When deciding to buy, hold or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Evoke Pharma have decreased by 75.13% in the past year. An investor who bought shares of Evoke Pharma at the beginning of the year would take a loss of $0.64 per share if they sold it today. The stock has fallen 16.7% over the past month, meaning an investor who bought shares on Jun. 1 would see a capital loss of $0.11.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Evoke Pharma stock currently has an RSI of 28.29, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
EVOK has a 52-week high of $1.67 and a 52-week low of 36 cents.
Read Next:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ginkgo Bioworks to Hold Special Meeting of Shareholders
Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET
BOSTON, Aug. 2, 2024 /PRNewswire/ — Ginkgo Bioworks Holdings, Inc. DNA “, Ginkgo”, ))), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock in a range of not less than one-for-twenty (1:20) and not more than one-for-forty (1:40), with the final ratio to be determined by the Board of Directors. Shareholders will also vote to approve Ginkgo’s Amended and Restated Certificate of Incorporation, which has been updated to permit officer exculpation and remove provisions related to our merger with Soaring Eagle Acquisition Corp. and our domestication process, which are no longer relevant to our business.
Additional information regarding the special meeting, including how to vote, are available via proxy materials filed by Ginkgo with the U.S. Securities and Exchange Commission (the “SEC”), and can be found here.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
MEDIA CONTACT:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-to-hold-special-meeting-of-shareholders-302210173.html
SOURCE Ginkgo Bioworks
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Siyata Announces Reverse Stock Split
Reverse Stock-Split to be effective on August 2, 2024
VANCOUVER, BC, July 31, 2024 /PRNewswire/ — Siyata Mobile Inc. SYTA SYTAW))) (“Siyata” or the “Company“), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that it will effect a 1-for-18 reverse stock split (“Reverse Stock Split”) of its common share, no par value per share (“Common Share”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on Friday, August 2, 2024, and the Company’s Common Share will commence trading on the Nasdaq Capital Market on a post-split basis at the opening of the market on August 2, 2024. The Company’s Common Share will continue to trade on the Nasdaq Capital Market under the Company’s existing trading symbol, “SYTA,” and a new CUSIP number 83013Q 806 has been assigned as a result of the Reverse Stock Split.
The Reverse Stock Split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. There is no guarantee the Company will meet the minimum bid price requirement.
The 1-for-18 reverse stock split (the “Ratio”) will automatically combine and convert 18 current shares of the Company’s Common Share into one issued and outstanding new share of Common Share. Each outstanding stock option, pre-funded warrant, share purchase warrant, and other convertible security of the Company convertible into pre-Reverse Stock Split Common Shares that has not been exercised or cancelled prior to the effective date of the implementation of the Reverse Stock Split will be adjusted pursuant to the terms of the instrument or plan governing such security on the same Reverse Stock Split Ratio described above, and each holder of such pre-Reverse Stock Split convertible securities will become entitled to receive post-Reverse Stock Split Common Shares pursuant to such adjusted terms. The Reverse Stock Split will not change the par value of the Common Share nor the authorized number of shares of Common Share, preferred stock or any series of preferred stock.
No fractional shares will be issued in connection with the Reverse Stock Split. All fractional shares will be rounded up to the next higher whole number.
The Company’s transfer agent, Computershare, will serve as exchange for the Reverse Stock Split. Registered shareholders holding pre-split shares of the Company’s Common Share electronically in book-entry form are not required to take any action to receive post-split shares. Shareholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to such broker’s particular processes, and will not be required to take any action in connection with the Reverse Stock Split. Holders of stock certificates will need to send their old physical certificates with a letter of transmittal to receive their new post-Reverse Stock Split certificate.
About Siyata Mobile
Siyata Mobile Inc. is a B2B global vendor of next generation Push-To-Talk over Cellular devices, cellular booster systems, and video monitoring solutions. Its portfolio of in-vehicle and rugged devices enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to increase situational awareness and save lives.
Its portfolio of enterprise grade and consumer cellular booster systems enables first responders and enterprise workers to amplify cellular signals in remote areas, inside structural buildings where signals are weak and within vehicles for the maximum cellular signal strength possible.
For its video monitoring system, Siyata integrates software that we license with off-the-shelf hardware providing our customers with an integrated advanced camera system for management and visual monitoring of their fleet vehicles.
Siyata’s Common Shares trade on the Nasdaq under the symbol “SYTA” and its previously issued warrants trade on the Nasdaq under the symbol “SYTAW.”
Visit siyatamobile.com and unidencellular.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Siyata’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Siyata’s filings with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites and social media have been provided as a convenience, and the information contained on such websites or social media is not incorporated by reference into this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/siyata-announces-reverse-stock-split-302210778.html
SOURCE Siyata Mobile Inc.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.